Current and emerging therapies for lupus nephritis

Journal of the American Society of Nephrology

Volumn 27, Issue 10, 2016, Pages 2929-2939

  Parikh, Samir V ^a   Rovin, Brad H ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; COMPLEMENT; CORTICOSTEROID; INTERFERON; MONOCLONAL ANTIBODY;

CORTICOSTEROID THERAPY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; REVIEW; FORECASTING; LUPUS NEPHRITIS;

ADRENAL CORTEX HORMONES; FORECASTING; HUMANS; LUPUS NEPHRITIS;

EID: 85012256114     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016040415     Document Type: Review

References (104)

1. Heller BI, Jacobson WE, Hammarsten JF. Effects ofCortisone inGlomerulonephritis and the Nephropathy of Disseminated Lupus Erythematosus. Am J Med 10: 520, 1951
2. Cameron JS: Lupus nephritis. J Am Soc Nephrol 10: 413-424, 1999
3. Pollak VE, Pirani CL, Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosus.1964. JAmSocNephrol 8: 1189-1198; discussion 1189-1195, 1997
4. Costenbader KH, Desai A, Alarcón GS, Hiraki LT, Shaykevich T, BrookhartMA, Massarotti E, Lu B, Solomon DH, Winkelmayer WC: Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from1995 to 2006.Arthritis Rheum 63: 1681-1688, 2011
5. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614-619, 1986
6. Ginzler EM, Bollet AJ, Friedman EA: The natural history and response to therapy of lupus nephritis. Annu Rev Med 31: 463-487, 1980
7. Appel GB, Contreras G, DooleyMA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112, 2009
8. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, Hillson JL, Meadows-Shropshire S, Kinaszczuk M, Merrill JT: Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheumatol 66: 379-389, 2014
9. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131, 2002
10. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, Group LI; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215-1226, 2012
11. Cervera R, KhamashtaMA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejía JC, Aydintug AO, Chwalinska-Sadowska H, de Ramón E, Fernández-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR; European Working Party on Systemic Lupus Erythematosus: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82: 299-308, 2003
12. Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS: Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 48: 542-545, 2009
13. Lech M, Anders HJ: The pathogenesis of lupus nephritis. J Am Soc Nephrol 24: 1357-1366, 2013
14. Houssiau FA, Vasconcelos C, D'Cruz D, SebastianiGD, de RamonGarrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61-64, 2010
15. Group AT; ACCESS Trial Group: Treatment of lupus nephritis with abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 66: 3096-3104, 2014
16. Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL: Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int 89: 235-242, 2015
17. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies inWegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100-105, 2008
18. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN; Hong Kong-Guangzhou Nephrology Study Group: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343: 1156-1162, 2000
19. Ginzler EM, DooleyMA, Aranow C, KimMY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219-2228, 2005
20. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N, Group A; ALMS Group: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl JMed 365: 1886-1895, 2011
21. Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, Hooi LS, Brunetta P, Maciuca R, Solomons N: Lupus nephritis: induction therapy in severe lupus nephritis-should MMF be considered the drug of choice? Clin J AmSoc Nephrol 8: 147-153, 2013
22. Tektonidou MG, Dasgupta A, Ward MM: Risk of End-stage Renal Disease in Patients with Lupus Nephritis, 1970 to 2015 A systematic review and Bayesian meta-analysis. Arthritis Rheum 2016. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26815601. Accessed May 6, 2016
23. Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, Nagaraja H, Indrakanti D, Rovin BH: Histologic versus clinical remission in proliferative lupus nephritis [published online ahead of print August 6, 2015]. Nephrology Dial Transplant doi:10.1093/ndt/gfv296
24. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980, 2004
25. Maltzman JS, Koretzky GA: Azathioprine: old drug, new actions. J Clin Invest 111: 1122-1124, 2003
26. Houssiau FA, D'Cruz D, Sangle S, Remy P, VasconcelosC, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R, Group MNT; MAINTAIN Nephritis Trial Group: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69: 2083-2089, 2010
27. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT; European League Against RheumatismandEuropean RenalAssociation-European Dialysis and Transplant Association: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71: 1771-1782, 2012
28. Gallagher KM, Lauder S, Rees IW, Gallimore AM, Godkin AJ: Type I interferon (IFN alpha) acts directly on human memory CD4+ T cells altering their response to antigen. J Immunol 183: 2915-2920, 2009
29. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19: 225-234, 2003
30. Ramos HJ, Davis AM, Cole AG, Schatzle JD, Forman J, Farrar JD: Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates. Blood 113: 5516-5525, 2009
31. RönnblomL, AlmGV, ElorantaML: The type I interferon system in the development of lupus. Semin Immunol 23: 113-121, 2011
32. Tucci M,Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F: Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 58: 251-262, 2008
33. Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, Kaverina N, Utset TO, Meehan SM,QuiggRJ, Meffre E, ClarkMR: In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 186: 1849-1860, 2011
34. Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, ClarkMR: Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 63: 865-874, 2011
35. Bao L, Haas M, Quigg RJ: Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 22: 285-295, 2011
36. Sekine H, Ruiz P, Gilkeson GS, Tomlinson S: The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol 49: 317-323, 2011
37. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS: Modulation of renal disease in MRL/lprmice genetically deficient in the alternative complement pathway factor B. J Immunol 164: 786-794, 2000
38. Wenderfer SE, Ke B, Hollmann TJ, Wetsel RA, Lan HY, Braun MC: C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J Am Soc Nephrol 16: 3572-3582, 2005
39. Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H: Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 44: 2097-2106, 2001
40. Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F: Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 154: 247-254, 2008
41. Foster MH: T cells and B cells in lupus nephritis. Semin Nephrol 27: 47-58, 2007
42. Kyttaris VC, Tsokos GC: T lymphocytes in systemic lupus erythematosus: an update. Curr Opin Rheumatol 16: 548-552, 2004
43. Crispín JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC: Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181: 8761-8766, 2008
44. Bettelli E, Carrier Y, GaoW, Korn T, Strom TB, OukkaM,Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238, 2006
45. Iikuni N, Lourenço EV, Hahn BH, La Cava A: Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol 183: 1518-1522, 2009
46. Kuhn A, Beissert S, Krammer PH: CD4(+) CD25 (+) regulatory T cells in human lupus erythematosus. ArchDermatol Res 301: 71-81, 2009
47. Davidson A: Targeting BAFF in autoimmunity. Curr Opin Immunol 22: 732-739, 2010
48. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W: Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 58: 2453-2459, 2008
49. Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF: Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferationinducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 22: 873-884, 2013
50. NeusserMA, LindenmeyerMT, Edenhofer I, Gaiser S, Kretzler M, Regele H, Segerer S, Cohen CD: Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 24: 98-107, 2011
51. Kyttaris VC,Wang Y, Juang YT,Weinstein A, Tsokos GC: Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol 178: 1960-1966, 2007
52. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229: 152-172, 2009
53. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258, 1996
54. DaikhDI,Wofsy D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 166: 2913-2916, 2001
55. Schiffer L, Sinha J, Wang X, Huang W, von GersdorffG, SchifferM,MadaioMP, Davidson A: Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 171: 489-497, 2003
56. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM,OrtmannWA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100: 2610-2615, 2003
57. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, ChenW, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP: Association of increased interferoninducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54: 2951-2962, 2006
58. ParikhSV, Malvar A,SongH, AlbertonV, Lococo B, Vance J, Zhang J, Yu L, Rovin BH: Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from nonresponders. Lupus Sci Med 2: e000112, 2015
59. Birmingham DJ, Hebert LA: The Complement System in Lupus Nephritis. Semin Nephrol 35: 444-454, 2015
60. Navratil JS, Korb LC, Ahearn JM: Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in themaintenance of immune tolerance. Immunopharmacology 42: 47-52, 1999
61. Walport MJ: Complement and systemic lupus erythematosus. Arthritis Res 4[Suppl 3]: S279-S293, 2002
62. Schifferli JA, SteigerG,Hauptmann G, Spaeth PJ, Sjöholm AG: Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest 76: 2127-2133, 1985
63. Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, Yu CY, Hebert LA, Rovin BH: The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 19: 1272-1280, 2010
64. Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S: Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 180: 1231-1238, 2008
65. Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S: The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 63: 1076-1085, 2011
66. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63: 3918-3930, 2011
67. Dooley MA, Houssiau F, Aranow C, D'Cruz DP, AskanaseA, RothDA, Zhong ZJ, Cooper S, FreimuthWW,Ginzler EM; BLISS-52 and-76 Study Groups: Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22: 63-72, 2013
68. Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW: The impact of tabalumab on the kidney in systemic lupus erythematosus: results from 2 phase 3 randomized, clinical trials [published online ahead of print May 24, 2016]. Lupus doi: 10.1177/0961203316650734
69. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P: B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 63: 3038-3047, 2011
70. Steinmetz OM, Lange-Hüsken F, Turner JE, Vernauer A, Helmchen U, Stahl RA, Thaiss F, Panzer U: Rituximab removes intrarenal B cell clusters in patientswith renal vascular allograft rejection. Transplantation 84: 842-850, 2007
71. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, DilhuydyMS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S,DöhnerH,LangerakAW,Ritgen M, KnebaM,Asikanius E,Humphrey K,Wenger M, Hallek M: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. NEngl J Med 370: 1101-1110, 2014
72. Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P: Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115: 4393-4402, 2010
73. Pollard RP, Abdulahad WH, Vissink A, Hamza N, Burgerhof JG,Meijer JM, VisserA,Huitema MG, Spijkervet FK, Kallenberg CG, Bootsma H, Kroese FG: Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis 72: 146-148, 2013
74. Miller JP, Stadanlick JE, Cancro MP: Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 176: 6405-6410, 2006
75. ThienM, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20: 785-798, 2004
76. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H: A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med 203: 393-400, 2006
77. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W: B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 67: 1011-1016, 2008
78. Cheng Q, Mumtaz IM, Khodadadi L, Radbruch A, Hoyer BF, Hiepe F: Autoantibodies fromlong-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis 72: 2011-2017, 2013
79. EspeliM, Bökers S,GiannicoG,DickinsonHA, Bardsley V, Fogo AB, Smith KG: Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 22: 296-305, 2011
80. Hiepe F, Dörner T, Hauser AE,Hoyer BF,Mei H, Radbruch A: Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7: 170-178, 2011
81. Grammer AC, Lipsky PE: B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5[Suppl 4]: S22-S27, 2003
82. Hainz N, Thomas S, Neubert K, Meister S, Benz K, Rauh M, Daniel C, WiesenerM, Voll RE, Amann K: The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron, Exp Nephrol 120: e47-e58, 2012
83. Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA: Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mousemodels of SLE. Int Immunopharmacol 12: 257-270, 2012
84. Weng J, Lai P, LvM, Lin S, LingW, Geng S, Luo C, Liu X, Du X: Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease. Clin Lab 59: 51-58, 2013
85. Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q,Waka A, Taddeo A,Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE: The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74: 1474-1478, 2015
86. Moreau P, Masszi T, Grzasko N, Bahlis NJ, HanssonM, Pour L, Sandhu I,Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de VeldeH, Richardson PG; TOURMALINE-MM1 Study Group: Oral Ixazomib, Lenalidomide, andDexamethasone forMultipleMyeloma.N Engl J Med 374: 1621-1634, 2016
87. Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, Lightstone L, Cairns T: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24: 3717-3723, 2009
88. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P: Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65: 2368-2379, 2013
89. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, Group BGLNT; BG9588 Lupus Nephritis Trial Group: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48: 719-727, 2003
90. Shock A, Burkly L, Wakefield I, Peters C, Garber E, Ferrant J, Taylor FR, Su L, Hsu YM, HuttoD, Amirkhosravi A,Meyer T, Francis J, Malcolm S, Robinson M, Brown D, Shaw S, Foulkes R, Lawson A, Harari O, Bourne T, Maloney A, Weir N: CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immuneresponses without thrombotic complications: an in vivo study. Arthritis Res Ther 17: 234, 2015
91. Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, GuY, ShiW,HuW, Liu Z, BaoH, Zeng C, Zhou M: Multitarget therapy for induction treatment of lupus nephritis: A randomized trial.Ann InternMed 162: 18-26, 2015
92. Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, Nakanishi T, Kakeda M, Gabazza EC, Mizutani H: Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells. PLoS One 7: e31465, 2012
93. Mathieson PW: Proteinuria and immunity-an overstated relationship? N Engl J Med 359: 2492-2494, 2008
94. Zavada J, Pesickova S, Rysava R, Olejarova M, Horák P, Hrncír Z, Rychlík I, Havrda M, Vítova J, Lukác J, Rovensky J, Tegzova D, Böhmova J, Zadrazil J, Hána J, Dostál C, Tesar V: Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: The Cyclofa-Lune study. Lupus 19: 1281-1289, 2010
95. Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL: Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann Rheum Dis 75: 30-36, 2016
96. Furie R, Merrill JT,Werth VT, Khamashta M, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S: Anifrolumab, an antiinterferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus. Am Coll Rheumatol 2015; Abstract #3223: San Francisco, CA
97. Biesecker G, Koffler D: Immunopathology of the membrane attack complex in systemic lupus erythematosus nephritis. Arthritis Rheum 25: 876-879, 1982
98. Barilla-Labarca ML, Toder K, Furie R: Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 148: 313-321, 2013
99. Gilkeson GS. Complement-Targeted Therapies in Lupus. Current Treat Options Rheum 1: 10-18, 2015
100. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC: C5a receptor (CD88) blockade protects againstMPO-ANCAGN. J AmSoc Nephrol 25: 225-231, 2014
101. Jayne DAG, Mao D: The Pharmacokinetics of Laquinimod and Mycophenolate Mofetil during Treatment of Active Lupus Nephritis. In: Form A ed., American Society of Nephrology Kidney Week: 2013, SA-PO1094
102. Aranow C, Vollenhoven R, Rovin BH: A Phase 2,Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Sirukumab in Patients with Active Lupus Nephritis. Abstract form, American College of Rheumatology National Meeting: 2015
103. Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ: C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 35: 2496-2506, 2005
104. Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, Gunnarsson I: IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment. BMC Immunol 16: 7, 2015